FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Stay up to date on FOLOTYN + Spectrum Pharmaceuticals

Sign up for updates to get news on FOLOTYN + Spectrum delivered to your inbox:

  • New interactive resources
  • Expert presentations
  • Treatment resources
  • Reimbursement support
  • Spectrum news + alerts

By signing up for updates I agree to receive emails from Spectrum Pharmaceuticals related to PTCL disease state education, treatment of relapsed or refractory PTCL, FOLOTYN, other Spectrum products, and Spectrum corporate news and events.

Email address: (Required)

Information you submit will be used as described in our Privacy Policy >, and by using this feature you agree to adhere to our Terms of Use >.